This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.
|Number of pages||10|
|Journal||Journal of Clinical Psychiatry|
|Issue number||8 SUPPL.|
|Publication status||Published - 1993|
ASJC Scopus subject areas
- Psychiatry and Mental health
- Clinical Psychology